



**Supplementary Figure 1 Quality Assessment of Diagnostic Accuracy Studies 2 (QUADAS-2) methodological quality summary.** The figure provides a concise overview of the methodological rigor and potential applicability concerns across the reviewed studies.

A




# B




**Supplementary Figure 2 Forest plot for studies based on the  $^{13}\text{C}$ -UBT for *H. pylori* infection in dyspeptic patients by urea dose.** A: Overall sensitivity for studies based on the  $^{13}\text{C}$ -UBT for *H. pylori* infection in dyspeptic patients by urea dose. B: Overall specificity for studies based on the  $^{13}\text{C}$ -UBT for *H. pylori* infection in dyspeptic patients by urea dose.

A




# B




**Supplementary Figure 3 Forest plot for studies based on the  $^{13}\text{C}$ -UBT for *H. pylori* infection in dyspeptic patients by time after urea administration.** A: Overall sensitivity for studies based on the  $^{13}\text{C}$ -UBT for *H. pylori* infection in dyspeptic patients by time after urea administration. B: Overall specificity for studies based on the  $^{13}\text{C}$ -UBT for *H. pylori* infection in dyspeptic patients by time after urea administration.

A






**B**




**Supplementary Figure 4 Forest plot for studies based on the  $^{13}\text{C}$ -UBT for *H. pylori* infection in dyspeptic patients by assessment technique.** A: Overall sensitivity for studies based on the  $^{13}\text{C}$ -UBT for *H. pylori* infection in dyspeptic patients by assessment technique. B: Overall specificity for studies based on the  $^{13}\text{C}$ -UBT for *H. pylori* infection in dyspeptic patients by assessment technique.

A




**B**




**Supplementary Figure 5 Forest plot for studies based on the <sup>14</sup>C-UBT for *H. pylori* infection in dyspeptic patients by urea dose. A: Overall sensitivity for studies based on the <sup>14</sup>C-UBT for *H. pylori* infection in dyspeptic patients by urea dose. B: Overall specificity for studies based on the <sup>14</sup>C-UBT for *H. pylori* infection in dyspeptic patients by urea dose.**

A




**B**




**Supplementary Figure 6 Forest plot for studies based on the <sup>14</sup>C-UBT for *H. pylori* infection in dyspeptic patients by time after urea administration. A: Overall sensitivity for studies based on the <sup>14</sup>C-UBT for *H. pylori* infection in dyspeptic patients by time after urea administration. B: Overall specificity for studies based on the <sup>14</sup>C-UBT for *H. pylori* infection in dyspeptic patients by time after urea administration.**

A



**B**



**Supplementary Figure 7 Forest plot for studies based on the <sup>14</sup>C-UBT for *H. pylori* infection in dyspeptic patients by assessment technique. A: Overall sensitivity for studies based on the <sup>14</sup>C-UBT for *H. pylori* infection in dyspeptic patients by assessment technique. B: Overall specificity for studies based on the <sup>14</sup>C-UBT for *H. pylori* infection in dyspeptic patients by assessment technique.**



**Supplementary Table 1 Likelihood ratios and diagnostic odds ratios for <sup>13</sup>C- and <sup>14</sup>C-UBTs for *H. pylori* infection.**

<sup>13</sup> C-UBT		
	Mean	95% CI
Positive likelihood ratio (LR+)	22.00	15.60-30.10
Negative likelihood ratio (LR-)	0.05	0.04-0.06
DOR	586.47	340.03-1011.51
<sup>14</sup> C-UBT		
Positive likelihood ratio (LR+)	10.10	5.74-16.90
Negative likelihood ratio (LR-)	0.06	0.04-0.08
DOR	226.50	102.57-500.15

LR: Likelihood ratio; DOR: diagnostic odds ratio.